PHILADELPHIA, Nov. 9, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony^® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced it has been chosen to present at the 12^th Annual Diabetes Technology Meeting which is being held November 8-10, 2012 at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

The presentation, entitled "Transdermal Continuous Glucose Monitoring – A Needle-Free Alternative to Invasive Sensors," will be given by Wayne Menzie, Echo's Director of Technology and Clinical Development.  The presentation is scheduled for Friday, November 9 at 10:50 AM EST during the Technologies for Metabolic Monitoring session.

"The selection of Echo Therapeutics as one of the companies to present at the Diabetes Technology Society's conference is a great opportunity for us to apprise the diabetes science and engineering community of the value of needle-free, continuous glucose monitoring in the hospital setting," said Patrick Mooney, M.D., Echo's Chairman and CEO.  "As we move towards commercialization in Europe next year, we look forward to sharing our progress at important medical and scientific meetings like the DTS."

"The numerous key opinion leaders in Europe and the US we have met with are very enthusiastic about the potential for Symphony to continuously monitor glucose levels in the hospital with an appropriate level of accuracy, safety, ease of use, and cost effectiveness," added David Walton, Echo's Vice President of Marketing and Commercial Development.  "Given my prior experience in successfully launching a CGM product in Europe, I am very encouraged by the prospects for Symphony to fulfill unmet needs in the hospital setting."

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude^® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio                                         
Director, Investor Relations and Corporate Communications
(215) 717-4104                                                 

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.